Clinical Trial Update: MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of MK-0646 (dalotuzumab), an IGF-1 receptor antibody, in stage IIIb/IV metastatic non-squamous non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MK-0646 (dalotuzumab) (dalotuzumab)

Snippet

Sponsor: University of Kansas | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED